Synchronous mRCC (N = 144 /EVENT = 130) | Metachronous mRCC (N = 70/EVENT = 63) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Univariable | Multivariable | Univariable | Multivariable | ||||||
Hazard ratio (95% CI) | P-value | Hazard ratio (95% CI) | P-value | Hazard ratio (95% CI) | P-value | Hazard ratio (95% CI) | P-value | ||
Risk group | Intermediate | 1 | 1 | ||||||
poor | 1.728 (1.156–2.584) | 0.0077 | 1.801 (0.766–4.235) | 0.1772 | |||||
Therapy | IT | 1 | 1 | 1 | 1 | ||||
TT | 1.858 (1.288–2.681) | 0.0009 | 1.696 (1.157–2.486) | 0.0068 | 2.019 (1.202–3.39) | 0.0079 | 2.019 (1.202–3.39) | 0.0079 | |
Treatment Free interval | ≥1 yr | 1 | 1 | ||||||
< 1 yr | 1.017 (0.473–2.184) | 0.9660 | 1.752 (0.995–3.084) | 0.052 | |||||
Gender | Male | 1 | 1 | ||||||
Female | 1.215 (0.777–1.901) | 0.3934 | 1.155 (0.670–1.993) | 0.6041 | |||||
Age (year) | 0.991 (0.975–1.007) | 0.2801 | 0.980 (0.951–1.009) | 0.1692 | |||||
Anemia | Normal | 1 | 1 | ||||||
Hb < 13.5(male)/12.0(Female) | 1.724 (1.142–2.600) | 0.0095 | 0.846 (0.427–1.675) | 0.6311 | |||||
Hypercalcemia | Normal | 1 | 1 | ||||||
> 10 mg/dL or 2.5 mmol/L | 1.166 (0.705–1.929) | 0.5499 | 0.995 (0.444–2.227) | 0.9897 | |||||
Neutrophilia | Normal | 1 | 1 | 1 | |||||
< 1500 or > 7500 | 2.497 (1.53–4.074) | 0.0002 | 2.105 (1.274–3.478) | 0.0037 | 0.918 (0.464–1.817) | 0.806 | |||
Elevated LDH | Normal | 1 | 1 | ||||||
1.5 X ULN | 1.482 (0.943–2.329) | 0.0883 | 1.491 (0.661–3.365) | 0.3357 | |||||
KPS | > 80 | 1 | |||||||
≤ 80 | 2.122 (0.779–5.779) | 0.1409 | |||||||
Thrombocytosis | Normal | 1 | 1 | ||||||
> 400 K | 1.700 (1.013–2.855) | 0.0448 | 1.054 (0.379–2.932) | 0.9199 |